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Purpose: To evaluate the efficacy of radiotherapy (RT) for early-stage nodal and extranodal marginal zone
lymphoma (MZL).
Materials and methods: Patients with stage I (n = 22) and stage II (n = 8) MZL, who were treated with RT were
reviewed. The primary tumor localisation was in the orbita (n = 12), stomach (n = 8), head and neck other than the
orbita (n = 8), breast (n = 1) and one case of marginal zone lymphoma of the skin (n = 1). The median radiotherapy
dose was 40 Gy (5 to 45 Gy).
Results: The median follow-up time was 103 months. The 5-year overall survival and event-free survival rates were
85 ± 7% and 71 ± 9%, respectively. There was no infield recurrence. Recurrence occurred outside of the radiation
field in six patients. The relapses were treated with salvage RT and had excellent local control (100%) at five years
after salvage RT.
Conclusions: Localized extranodal MZL have an excellent prognosis following moderate-dose RT. RT is also an
effective salvage therapy in cases of localized recurrence. Further clinical studies should evaluate the optimal dose
for MZL.
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In 1984, Isaacson and Wright [1] described a group of
lymphomas that derived from mucosa-associated lymph-
oid tissue (MALT). Today these lymphomas are well
established as a distinct subtype of the marginal zone
lymphomas (MZL) in the non-Hodgkin’s lymphoma
classification. The most common localization is the
gastrointestinal tract [2], especially the stomach, but
MALT lymphomas arise from other epithelial structures
as well. Those include regions in the head and neck area,
e.g. the salivary glands, the thyroid gland or the orbita,
breast and, though not typically mucosa-associated, in
some cases the skin. MZL may also occur primarily in
the lymph nodes. The main characteristic of MALT
lymphoma is its indolent behaviour. They are commonly
diagnosed in localized stages (Ann-Arbor stage I and II)
and stay localized for a long time. Previous studies have
shown excellent outcomes after radiotherapy in treatment
of MALT lymphoma as an organ-preserving treatment
modality [3] as has also been shown for other indolent* Correspondence: khfmed@yahoo.com
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reproduction in any medium, provided the orlymphoma subtypes [4]. We report the outcomes of a
retrospective analysis of 30 patients with stage I-II MALT-
lymphoma treated with radiotherapy at our Institution.Methods
The medical records of 36 patients treated with radio-
therapy for Stage I and II MALT lymphoma at our
department between 1988 and 2010 were retrospectively
reviewed. Inclusion criteria were: histological diagnosis
of MALT lymphoma, no transformed MALT lymphoma
and no previous treatment. Patients who were treated
with chemotherapy previous to radiation (n = 6) were
excluded. 30 patients fulfilled the inclusion criteria.
Written informed consent was obtained from the patient
for publication of this report.Patient characteristics
Thirteen men (43%) and seventeen women (57%) at a
median age of 64 years (range 43-85y) at diagnosis were
evaluated for this retrospective analysis.
Twenty-two patients (73%) presented with MALT
lymphoma Ann-Arbor stage I and eight patients (27%)
had lymphoma diagnosed in Ann-Arbor stage II.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Deinbeck et al. Radiation Oncology 2013, 8:2 Page 2 of 5
http://www.ro-journal.com/content/8/1/2The majority of patients had extranodal disease (90%).
The most common localization in extranodal lymphoma
were the orbita (12 patients, 40%), stomach (8 patients,
27%) and head and neck (5 patients, 17%). One of the
patients with lymphoma of the parotid gland had diagnosed
Sjögren’s syndrome. One patient (3%) had a MALT
lymphoma of the breast and another patient (3%) was
diagnosed with primary cutaneous lymphoma. Only
10% of the patients presented with nodal disease. The
characteristics of the 30 patients are summarized in
Table 1.
Staging
Upper endoscopy and gastric biopsies were carried out
in all the patients with gastric lymphoma, but were not
routinely performed in the nongastric cases. H.pylori
was documented in biopsy specimens in 2 of the 8
patients with gastric lymphoma. H.p.- eradication therapy
prior to RT was unsuccessful Staging included complete
blood count, bone marrow biopsy, lactate dehydrogenase
(LDH) and appropriate site-specific imaging with CT and/
or MRI in all patients. In addition PET-CT was performed
in 2 patients.
Treatment
RT with 6 – 15 megavoltage photon beams was delivered
using a linear accelerator. In one patient with lymphoma
of the skin electron beams were used. The medianTable 1 Patient characteristics





Median (range) 64 years (43 – 85 years)
Primary site
Orbital adnexa 12 (40%)
Stomach 8 (27%)
Head and neck 5 (17%)









Missing 1 (3%)radiotherapy dose was 40 Gy (5 to 45 Gy), delivered at a
daily dose of 1.5 to 3.0 Gy. The radiotherapy portals
included at least the whole involved organ or nodal region.
Eight patients received extended field RT (6 patients with
gastric MALT and 2 with nodal MZL). Of the eight
patients with gastric MALT lymphoma 6 were treated
with abdominal bath and two with irradiation of the whole
stomach and the perigastric lymph nodes. Two of the gas-
tric MALT patients had previously been treated with
helicobacter-pylory eradication therapy, with no success.
Two of the patients with nodal disease received mantle
field RT and one involved field RT. Patients with orbital
lymphoma received irradiation of the whole orbit without
lense shielding. Patients with involvement of the breast,
thyroid and parotid gland were treated with RT of the
whole organ and adjacent lymph nodes. No patient was
treated with chemotherapy.
Follow up
Patients were clinically examined weekly during RT. Six
to eight weeks after the end of the treatment patients
were restaged for response and evidence of residual
disease. Restaging included a physical examination,
relevant radiologic studies, endoscopy in gastric cases
and laboratory profiles. The first visit took place 6–8 weeks
after radiation therapy, further follow up was every
3 months for the first year, every 6 months for the
next 5 years, and then every year including a physical
examination and a site-specific MRI or CT scan.
Treatment failure was defined as any kind of recurrence of
lymphoma. The first sites of recurrence were recorded as
either inside or outside the RT field. Acute side effects
were graded according to Common Toxicity Criteria
(CTC-3.0) and late sequelae were evaluated using the
LENT-SOMA scoring system.
Statistical methods
Overall Survival (OS) was defined as death from any
cause and Event Free Survival (EFS) was defined as the
time to relapse or death regardless of cause. OS and EFS
rates were estimated using the method of Kaplan and
Meier. Log rank tests were performed to compare event-
time distributions between different groups. The results
were regarded as significant if p was < 0.05.
Results
Twenty-four patients (80%) achieved a CR after being
treated with RT. In four cases (13%) a PR was achieved.
In two patients (7%) response could not specifically be
defined, due to death before evaluation and missing data.
During a median follow-up time of 103 months, there were
14 events (relapse or death regardless of cause). Ten
patients (33%) died during follow-up. The 5- and 7-year
OS was 85 ± 7% and 80 ± 8%, respectively. The 5- and
Figure 2 OS for patients with Ann Arbor stage 1 and 2.
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(Figure 1). Stage I disease was significantly associated with
a better OS (p = 0.020). The median OS for patients in
stage I was not reached and was 104 months (CI 95%
11–197 months) for patients in stage II, respectively
(Figure 2). The 5 and 7-year OS was 94 ± 6% and 88 ± 8%
for patients in stage I and 58 ± 19% and 58 ± 19% for
stage II, respectively. Female gender (p = 0.137) showed
a tendency towards better OS. The median OS was not
reached for female patients and 104 months (CI 95%
98–110 months) for male patients, respectively. The 5 and
7-year OS was 93 ± 7% and 85 ± 10% for female patients
and 85 ± 10% and 74 ± 13% for male patients, respectively.
No in-field relapses were observed. A total of 6 patients
had out-field recurrence (20%). The median time to recur-
rence after RT was 26 months (range 8–35 months). Five
of the six recurrences occurred after complete remission
(CR), one patient had partial remission (PR) after initial
treatment: In the first case, recurrence occurred eight
months after the end of RT. The patient originally pre-
sented with stage I breast MALT lymphoma. She received
involved field radiation with 40 Gy and achieved CR. The
recurrence occurred in the subcutaneous tissue of the
ipsilateral upper arm eight months after primary RT and
was treated again with RT. After that, the patient relapsed
four more times. Relapses were localized to the head and
neck area and the orbita and were treated by RT each time.
The median time between the relapses was 24 months. No
recurrence was detected 6 months after the last RT.
The second patient had MZL in axillary nodes and
relapsed in the parotid gland 24 months after mantle
field irradiation. This recurrence was surgically resected.
He was free of disease 6 months after the parotidectomy.
The third patient presented with orbital lymphoma
and received an involved field RT with 40 Gy. RelapseFigure 1 Kaplan-Meier OS and EFS curves of the whole cohort.was observed in the mucosa of the mouth 27 months
after initial treatment and it was treated with 40 Gy
involved field RT. A second relapse occurred in the axillary
nodes 26 months later and was treated with 50 Gy. This
patient was recurrence free for a further 30 months.
The fourth patient presented with primary lymphoma
of the orbital adnexa and relapsed after 31 months in a
cervical lymph node. Due to age, no further treatment
was administered and the patient was alive with disease
at the end of follow-up.
The fifth outfield recurrence was also detected in a
patient with orbital lymphoma, who was treated with 30 Gy
involved field. Thirty-five months after the end of therapy,
recurrence occurred in the lung tissue. The recurrence was
completely removed by surgery. The patient has been in
CR without new recurrences for 48 months.
The sixth patient received involved field RT with 40 Gy
for orbital lymphoma and relapsed after 35 months in the
cervical, mediastinal, paraaortal and iliacal lymph nodes.
Salvage chemotherapy was administered, but the patient
died four months after the diagnosis of recurrence.
Toxicity
There were no treatment-related deaths. Acute toxicity
was seen in patients with lymphoma of the orbita. The
most common side effect was ≤ grade 3 conjunctivitis
(31%). The most common late toxicity was cataract
formation with the need of surgical extraction of the lense
in four patients. One patient lost sight after irradiation
with 40 Gy Of the eight patients with lymphoma of the
stomach, three (37%) showed ≤ grade 3 acute side effects
including diarrhea, nausea and stomach pain. Acute ≤
grade 3 mucositis, xerostomia and dysphagia were
observed in four cases of head and neck lymphoma.
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We report our single institutional experience in patients
with stage I and II nodal and extranodal marginal zone
lymphoma who were primarily treated with RT alone at
our department. Regarding the distribution of anatomic
sites, Thieblemont et al. reported that half of the patients
in their study of 108 patients had GI involvement, about
10% each had disease of the orbit, skin and lung [5].
Goda et al. reported a higher proportion of patients with
disease in the orbital adnexa (43%) than patients with
MALT lymphoma of the stomach (15%). This is in line
with our study where most patients had disease of the
orbit (40%), followed by the stomach (27%) [6]. We
observed no in-field recurrence after a median follow-up
time of 103 months, which demonstrates that RT-alone
is highly effective in achieving local control for localized
MALT lymphoma. The 5-year OS rate of 85% in our
cohort is in line with other studies reporting 5-year OS
rates between 87 and 98% [3,6-11] for stages I and II.
For the 5-year LC excellent rates between 95% and 100%
[3,9-12] have been described. In our study no local
relapses were observed after median radiation doses of
40 Gy. However, marginal zone lymphoma tends to
show relatively high systemic relapse rates with an
emphasis on other mucosal sites. Relapse rates have
been reported between 14 and 43% [6-9,13,14]. Moreover,
several authors reported fewer relapses in patients with
gastric lymphoma than in other MALT sites. In a study of
70 stage I and II patients, Tsang et al. found that patients
with gastric and thyroid lymphoma showed no relapses at
all, whereas 22% of the patients with MALT lymphoma of
other origins developed distant recurrences [9]. Similar
observations were made by Goda et al. in 192 patients
where no patient with gastric MALT lymphoma showed
disease progression [6]. In another series of 108 patients,
Thieblemont et al. also described a higher recurrence rate
for non-GI lymphoma than for patients with involvement
of the stomach [5]. For MALT lymphoma of the salivary
glands and the orbital adnexa, relapse rates of up to 37%
and 39%, respectively have been reported [15,16]. In a
series of 17 patients treated with radiation alone for gastric
MALT lymphoma, Schechter et al. found an EFS of 100%
after a median follow-up time of 27 months (11–
68 months) [17]. This is in line with our study, where only
patients with lymphoma of the ocular adnexa, breast and
primary nodal disease showed relapse whereas patients
with gastric lymphoma did not develop any recurrences.
Regarding relapse patterns, several authors have described
that additional mucosal sites and the other half of a paired
organ are more often involved than lymph nodes [7,11]. In
our study, recurrence occurred in lymph nodes in two
cases; three others recurred in mucosal sites including the
oral mucosa, the parotid gland and the lung tissue. One
patient’s recurrence was in the subcutaneous tissue.Relapsed disease can generally be easily treated by another
course of RT [6,7,9]. In our study, treatment for relapses
was quite heterogeneous. One patient did not receive any
further treatment due to age. Two patients were treated
surgically and were alive without disease at the time of
follow-up. Another patient received salvage chemotherapy
but died of lymphoma. Two more patients received
another course of RT and both of their lymphomas were
controlled locally but further relapses were discovered at
other sites. One of those two is still alive and was in remis-
sion at the time of follow-up, the other one died due to
breast cancer. In summary, administering RT in recurrent
disease provides very good local control.
Data for primary nodal MZL is scarce. In a series of 47
patients with primary nodal disease, Tsang et al. found
MZL to be associated with worse outcome than in
patients with MALT-lymphoma [9]. OS rates up to 79%
with short time to relapse and a failure-free survival of
22% were described in a series with a relatively high
proportion of patients with stage I and II disease (59%)
[18]. The treatment of this entity is still a topic of
discussion and includes the use of various chemotherapy
regimens as well as the CD20-antibody Rituximab
[19,20] In our series, three patients had stage I primary
nodal disease at the axillar, supraorbital and cervical
lymph nodes, respectively. All three received a total
radiation dose of 40 Gy, two of them in form of a mantle
field, one as RT of the involved lymph node region.
None of the patients received chemotherapy. The
patient with primary axillar involvement relapsed after
24 months in the parotid gland, which was treated
surgically. All three patients are alive without disease. As
we have a limited number of patients, no statement can
be made about whether chemotherapy is necessary in
patients with low stage primary nodal disease or not, but
RT alone could be considered for these cases. RT doses
are still a topic of discussion. Some authors recommend
RT doses between 25 and 35 Gy for patients with MALT
lymphoma [6,7,11,21,22]. For orbital lymphoma, doses
between 25 and 30 Gy seem to be sufficient to obtain
durable LC and OS [22-24]. In a recent randomized
phase III trial by Lowry et al., patients with indolent
lymphoma - predominantly follicular and MALT lymph-
oma – were treated with 40 to 45 Gy or 24 to 30 Gy,
respectively. No difference in response to treatment, LC,
EFS and OS was found between the two groups, but a
tendency to reduced toxicity could be observed [25].
Contrary to this, Fakhrian et al. investigated stage I-III
follicular lymphoma in 50 patients and observed in-field
recurrence only in patients who received a RT dose
lower than 26 Gy [26]. In the current study only two
patients received a radiation dose lower than 30 Gy, thus
we cannot draw any conclusions regarding radiation
doses lower than 30°Gy. However, LC and OS were
Deinbeck et al. Radiation Oncology 2013, 8:2 Page 5 of 5
http://www.ro-journal.com/content/8/1/2similar for patients receiving RT doses of less than or
more than 36 Gy in our cohort. Thus, patients in our
group had no benefit of higher radiation doses. The use
of chemotherapy and the monoclonal CD20-antibody
rituximab should be reserved for patients with stage III
and IV disease [27].
Conclusion
RT is a feasible treatment option for early stage MALT
lymphoma with excellent LC and OS. The optimal
treatment for recurrent disease remains to be defined and
mainly depends on the site of relapse (systemic vs. local).
Whether or not additional chemotherapy and/or antibody
treatment may be beneficial in patients with primary
localized nodal disease still remains to be determined by
studies with larger patient numbers. RT is also an effective
salvage therapy in cases of localized recurrence. Further
clinical studies should evaluate the optimal dose for MZL.
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